Ontruzant® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL

Before prescribing ONTRUZANT, please read the accompanying
Prescribing Information, including the Boxed Warning about cardiomyopathy,
infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.


THE ORGANON ACCESS PROGRAM

CAN HELP ANSWER QUESTIONS ABOUT:

  • Benefit investigations
  • Billing and coding
  • Co-pay assistance for eligible patients
  • Prior authorizations and appeals
  • Referral to the Organon Patient Assistance Program for eligibility determination (provided through the Organon Patient Assistance Program Inc.)
  • Product distribution
  • Sign up With the Electronic Enrollment Form With E-Signature



 WELCOME TO

Welcome to The Organon Access Program for ONTRUZANT® (trastuzumab-dttb)

ARE YOU A US HEALTH CARE PROFESSIONAL?

Please choose